Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study

American Heart Journal

Volumn 187, Issue , 2017, Pages 19-28

  Bagai, Akshay ^a   Peterson, Eric D ^b   McCoy, Lisa A ^b   Effron, Mark B ^c   Zettler, Marjorie E ^c   Stone, Gregg W ^d   Henry, Timothy D ^e   Cohen, David J ^f   Schulte, Phillip J ^g   Anstrom, Kevin J ^b   Wang, Tracy Y ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Lilly Corporate Center   (United States)

^d Department of Medicine   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR INHIBITOR; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CLINICAL PRACTICE; DEATH; DRUG POTENCY; DRUG SUBSTITUTION; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOCYTE FUNCTION ANALYZER; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; BRAIN ISCHEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; THROMBOCYTE;

AGED; BLOOD PLATELETS; BRAIN ISCHEMIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 85013789060     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.02.003     Document Type: Article

References (49)

1. 1. Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007), 1505–1516.
2. 2. Brar, S.S., ten Berg, J., Marcucci, R., et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58 (2011), 1945–1954.
3. 3. Bonello, L., Pansieri, M., Mancini, J., et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58 (2011), 467–473.
4. 4. Price, M.J., Berger, P.B., Teirstein, P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305 (2011), 1097–1105.
5. 5. Trenk, D., Stone, G.W., Gawaz, M., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel To Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59 (2012), 2159–2164.
6. 6. Collet, J.P., Cuisset, T., Range, G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367 (2012), 2100–2109.
7. 7. Chin, C.T., Wang, T.Y., Anstrom, K.J., et al. Treatment with adenosine diphosphate receptor inhibitors—ongitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. Am Heart J 162 (2011), 844–851.
8. 8. Wang, T.Y., Henry, T.D., Effron, M.B., et al. Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome Prospective Open Label Antiplatelet Therapy study. Circ Cardiovasc Interv, 8, 2015, e001712.
9. 9. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
10. 10. Price, M.J., Angiolillo, D.J., Teirstein, P.S., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a Verifynow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124 (2011), 1132–1137.
11. 11. Bagai, A., Peterson, E.D., Honeycutt, E., et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the Translate-ACS study. Eur Heart J Acute Cardiovasc Care 4 (2015), 499–508.
12. 12. Bagai, A., Wang, Y., Wang, T.Y., et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv 7 (2014), 585–593.
13. 13. Mathews, R., Peterson, E.D., Chen, A.Y., et al. In-hospital major bleeding during ST-elevation and non–ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®–GWTG™. Am J Cardiol 107 (2011), 1136–1143.
14. 14. Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
15. 15. Serebruany, V.L., Steinhubl, S.R., Berger, P.B., et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005), 246–251.
16. 16. Stone, G.W., Witzenbichler, B., Weisz, G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
17. 17. Aradi, D., Komocsi, A., Price, M.J., et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 167 (2013), 2140–2148.
18. 18. Parodi, G., Marcucci, R., Valenti, R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306 (2011), 1215–1223.
19. 19. Ahn, S.G., Lee, S.H., Yoon, J.H., et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the verifynow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 5 (2012), 259–267.
20. 20. Park, D.W., Ahn, J.M., Song, H.G., et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 165 (2013), 34–42.e31.
21. 21. Angiolillo, D.J., Saucedo, J.F., Deraad, R., et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol 56 (2010), 1017–1023.
22. 22. Gurbel, P.A., Bliden, K.P., Butler, K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (2010), 1188–1199.
23. 23. Diodati, J.G., Saucedo, J.F., French, J.K., et al. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv 6 (2013), 567–574.
24. 24. Rollini, F., Franchi, F., Cho, J.R., et al. A head-to-head pharmacodynamic comparison of prasugrel vs. Ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 37 (2016), 2722–2730.
25. 25. Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007), 2001–2015.
26. 26. Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361 (2009), 1045–1057.
27. 27. Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
28. 28. Sibbing, D., Schulz, S., Braun, S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8 (2010), 250–256.
29. 29. Cuisset, T., Cayla, G., Frere, C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-st elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. Eur Interv 5 (2009), 325–329.
30. 30. Patti, G., Pasceri, V., Vizzi, V., et al. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 107 (2011), 995–1000.
31. 31. Gurbel, P.A., Becker, R.C., Mann, K.G., et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 50 (2007), 1822–1834.
32. 32. Aradi, D., Kirtane, A., Bonello, L., et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36 (2015), 1762–1771.
33. 33. Coleman, C.I., Limone, B.L., Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Am J Cardiol 112 (2013), 355–362.
34. 34. Straub, N., Beivers, A., Lenk, E., et al. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb Haemost 111 (2014), 290–299.
35. 35. Hamm, C.W., Bassand, J.P., Agewall, S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32 (2011), 2999–3054.
36. 36. Aradi, D., Storey, R.F., Komocsi, A., et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35 (2014), 209–215.
37. 37. Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 124 (2011), 2574–2609.
38. 38. Jneid, H., Anderson, J.L., Wright, R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 60 (2012), 645–681.
39. 39. Bonello, L., Camoin-Jau, L., Arques, S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008), 1404–1411.
40. 40. Bonello, L., Camoin-Jau, L., Armero, S., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103 (2009), 5–10.
41. 41. Siller-Matula, J.M., Francesconi, M., Dechant, C., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167 (2013), 2018–2023.
42. 42. Hazarbasanov, D., Velchev, V., Finkov, B., et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 34 (2012), 85–90.
43. 43. Christ, G., Siller-Matula, J.M., Francesconi, M., et al. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open, 4, 2014, e005781.
44. 44. Damman, P., Varenhorst, C., Koul, S., et al. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). Am J Cardiol 113 (2014), 64–69.
45. 45. Alexopoulos, D., Goudevenos, J.A., Xanthopoulou, I., et al. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Int J Cardiol 168 (2013), 5329–5335.
46. 46. Sherwood, M.W., Wiviott, S.D., Peng, S.A., et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the us: insights from the National Cardiovascular Data Registry. J Am Heart Assoc, 3, 2014, e000849.
47. 47. Gandhi, S., Zile, B., Tan, M.K., et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian Acute Coronary Syndrome Reflective. Can J Cardiol 30 (2014), 1725–1731.
48. 48. Aradi, D., Tornyos, A., Pinter, T., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63 (2014), 1061–1070.
49. 49. Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.